News
Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...
Zacks Investment Research on MSN6d
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?Novartis AG NVS, a Swiss pharma giant, is scheduled to report second-quarter 2025 results on July 17. The Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback